Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers

Maria Vittoria Cossu, Dario Cattaneo, Serena Fucile, Paolo Pellegrino, Sara Baldelli, Valeria Cozzi, Amedeo Capetti, Emilio Clementi, Maria Vittoria Cossu, Dario Cattaneo, Serena Fucile, Paolo Pellegrino, Sara Baldelli, Valeria Cozzi, Amedeo Capetti, Emilio Clementi

Abstract

We designed two Phase I studies that assessed healthy volunteers in order to evaluate the safety and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a nonsteroidal antiinflammatory drug. We designed these studies with the aim of designing a Phase II trial to evaluate the drugs' efficacy in patients affected by Duchenne muscular dystrophy. For the first trial, ISOFEN1, a single-dose, randomized-sequence, open-label, active control, three-treatment cross-over study, was aimed at comparing the pharmacokinetics of ibuprofen 200 mg and isosorbide dinitrate 20 mg when given alone and concomitantly. The pharmacokinetics of ibuprofen given alone versus ibuprofen given concomitantly with isosorbide dinitrate were similar, as documented by the lack of statistically significant differences in the main drug's pharmacokinetic parameters (time to maximal concentration [Tmax], maximal concentration [Cmax], area under the curve [AUC]0-t, and AUC0-∞). Similarly, we found that the coadministration of ibuprofen did not significantly affect the pharmacokinetics of isosorbide dinitrate. No issues of safety were detected. The second trial, ISOFEN2, was a single-site, dose titration study that was designed to select the maximum tolerated dose for isosorbide dinitrate when coadministered with ibuprofen. Eighteen out of the 19 enrolled subjects tolerated the treatment well, and they completed the study at the highest dose of isosorbide dinitrate applied (80 mg/day). One subject voluntarily decided to reduce the dose of isosorbide dinitrate from 80 mg to 60 mg. The treatment-related adverse events recorded during the study were, for the large majority, episodes of headache that remitted spontaneously in 0.5-1 hour - a known side effect of isosorbide dinitrate. These studies demonstrate that the combination of isosorbide dinitrate and ibuprofen does not lead to pharmacokinetic interactions between the two drugs; they also demonstrate that the combination of isosorbide dinitrate and ibuprofen has optimal tolerability and safety profiles that are similar to those previously reported for isosorbide dinitrate and ibuprofen given alone.

Keywords: adverse events; coadministration; ibuprofen; isosorbide dinitrate; pharmacokinetic profile.

Figures

Figure 1
Figure 1
Flow chart of the ISOFEN2 study. Abbreviations: IBU, ibuprofen; ISO, isosorbide dinitrate; DBP, diastolic blood pressure.
Figure 2
Figure 2
Pharmacokinetic profiles of isosorbide and ibuprofen after the administration of ISO, ibuprofen, or their combination. Notes: (A) Ibuprofen profile; (B) isosorbide profile representing the mean (standard deviation) plasma drug concentrations over time, as measured in healthy volunteers (n=12) given each drug alone (black circles) or in combination (white circles). Abbreviations: ISO, isosorbide dinitrate; n, number.
Figure 3
Figure 3
Time course of diastolic blood pressure variations during the study. Notes: Diastolic blood pressure was measured at the different study visits in which ISO doses were up-titrated from 20 mg to 80 mg once daily at predose and 1 hour and 3 hours postdose. Abbreviation: ISO, isosorbide dinitrate.
Figure 4
Figure 4
Time course of systolic blood pressure variations during the study. Notes: Systolic blood pressure was measured at the different study visits in which isosorbide doses were up-titrated from 20 mg to 80 mg once daily at predose and 1 hour and 3 hours postdose. Abbreviation: ISO, isosorbide dinitrate.

References

    1. Dubowitz V. Prednisone for Duchenne muscular dystrophy. Lancet Neurol. 2005;4(5):264.
    1. Ruegg UT. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol. 2013;26(5):577–584.
    1. Jarmin S, Kymalainen H, Popplewell L, Dickson G. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther. 2014;14(2):209–230.
    1. Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011;19(5):830–840.
    1. Liu N, Williams AH, Maxeiner JM, et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest. 2012;122(6):2054–2065.
    1. Wang L, Zhou L, Jiang P, et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther. 2012;20(6):1222–1233.
    1. Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol. 2010;67(6):771–780.
    1. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol. 2001;155(1):123–131.
    1. Rando TA. Role of nitric oxide in the pathogenesis of muscular dystrophies: a “two hit” hypothesis of the cause of muscle necrosis. Microsc Res Tech. 2001;55(4):223–235.
    1. Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 2008;456(7221):511–515.
    1. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119(3):624–635.
    1. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev. 2001;81(1):209–237.
    1. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299(5608):896–899.
    1. Wehling-Henricks M, Oltmann M, Rinaldi C, Myung KH, Tidball JG. Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. Hum Mol Genet. 2009;18(18):3439–3451.
    1. Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000;11(5):1859–1874.
    1. Cazzato D, Assi E, Moscheni C, et al. Nitric oxide drives embryonic myogenesis in chicken through the upregulation of myogenic differentiation factors. Exp Cell Res. 2014;320(2):269–280.
    1. Colussi C, Mozzetta C, Gurtner A, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A. 2008;105(49):19183–19187.
    1. Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner SC. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS One. 2008;3(10):e3387.
    1. Filippin LI, Moreira AJ, Marroni NP, Xavier RM. Nitric oxide and repair of skeletal muscle injury. Nitric Oxide. 2009;21(3–4):157–163.
    1. De Palma C, Clementi E. Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol. 2012;46(3):682–692.
    1. Buono R, Vantaggiato C, Pisa V, et al. Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells. 2012;30(2):197–209.
    1. Cordani N, Pisa V, Pozzi L, Sciorati C, Clementi E.Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation Stem CellsEpub October292013
    1. Brunelli S, Sciorati C, D’Antona G, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A. 2007;104(1):264–269.
    1. Sciorati C, Miglietta D, Buono R, et al. A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res. 2011;64(3):210–217.
    1. Sciorati C, Staszewsky L, Zambelli V, et al. Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacol Res. 2013;73:35–43.
    1. Sciorati C, Buono R, Azzoni E, et al. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol. 2010;160(6):1550–1560.
    1. D’Angelo MG, Gandossini S, Martinelli Boneschi F, et al. Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res. 2012;65(4):472–479.
    1. Fung HL, McNiff EF, Ruggirello D, Darke A, Thadani U, Parker JO. Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br J Clin Pharmacol. 1981;11(6):579–589.
    1. Bushra R, Aslam N. An overview of clinical pharmacology of ibuprofen. Oman Med J. 2010;25(3):155–161.
    1. Farrar H, Letzig L, Gill M. Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780(2):341–348.
    1. Zhao X, Chen D, Li K, Wang D. Sensitive liquid chromatographic assay for the simultaneous determination of ibuprofen and its prodrug, ibuprofen eugenol ester, in rat plasma. Yakugaku Zasshi. 2005;125(9):733–737.
    1. Verma RK, Garg S. A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations. J Pharm Biomed Anal. 2002;30(3):583–591.
    1. Stockis A, De Bruyn S, Deroubaix X, et al. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab) Eur J Pharm Biopharm. 2002;53(1):49–56.
    1. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM) Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: Center for Drug Evaluation and Research (CDER); 2001. [Accessed January 10, 2013]. Available from: .
    1. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP) Guideline on the Investigation of Bioequivalence. London, UK: European Medicines Agency; 2010. [Accessed January 10, 2013]. Available from: .
    1. Finanger Hedderick EL, Simmers JL, Soleimani A, et al. Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders. Neurology. 2011;76(11):960–967.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi